Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS).

Authors: Tomasz Jankowski, Tibor Csőszi, Laszlo Urban, Tunde Nagy, Rodryg Ramlau, Maria Cholakova, Nataliya Chilingirova, Andrzej Mruk, Szabolcs Soter, Krassimir Dimitrov Koynov, Marek Kotlarski, Romina Girotti, Ilgen Mender, Marcel Mitsunaga, Oleg Tudos, Matthew Failor, Bin Yao, Vlad Vitoc, Sergei Gryaznov, Victor Zaporojan

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.8585

Source: Full article

---

Abstract

8585